CD8A and neoplasm: Our investigation demonstrates that LLL not only sustains CD8+ T‐cell functionality in the tumor, but also selectively enriches for the progenitor‐like and memory‐committed Tpex subset, critical for long‐term immune surveillance.[53] This immunometabolic axis provides a novel therapeutic angle to overcome T‐cell exhaustion and dysfunction in solid tumors.